Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Wall Street’s consensus rating is “Moderate Buy”: Five of seven analysts recommend buying Satellos Bioscience, while one rates it a hold and one a sell. The average 12-month price target is $19.75, versus a recent share price of $8.70.
• Institutional interest increased: AWM Investment Company raised its Satellos position by 41.9% in the second quarter to 305,000 shares, worth approximately $2.34 million.
• Financial results missed expectations: Satellos reported a quarterly loss of $0.56 per share, wider than the $0.38 loss analysts expected. Analysts project a full-year loss of approximately $2.08 per share.

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE - Get Free Report) have received an average rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $19.75.

Several research firms recently issued reports on MSLE. Wells Fargo & Company set a $18.00 price target on Satellos Bioscience in a research report on Thursday, July 9th. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Satellos Bioscience in a research note on Monday, August 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Satellos Bioscience in a report on Friday, August 7th.

Institutional Investors Weigh In On Satellos Bioscience

A hedge fund recently raised its position in Satellos Bioscience stock. AWM Investment Company Inc. boosted its holdings in Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) by 41.9% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 305,000 shares of the company's stock after acquiring an additional 90,000 shares during the period. AWM Investment Company Inc. owned about 1.46% of Satellos Bioscience worth $2,338,000 at the end of the most recent quarter.

Satellos Bioscience Price Performance

Shares of NASDAQ MSLE opened at $8.70 on Monday. The stock's 50 day moving average price is $9.49 and its two-hundred day moving average price is $7.99. Satellos Bioscience has a 52-week low of $5.30 and a 52-week high of $13.39. The stock has a market capitalization of $184.61 million, a P/E ratio of -4.53 and a beta of 1.53.

Satellos Bioscience (NASDAQ:MSLE - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.18). On average, analysts anticipate that Satellos Bioscience will post -2.08 EPS for the current year.

About Satellos Bioscience

Satellos Bioscience Inc is a biotechnology company focused on developing regenerative medicines for conditions involving skeletal muscle damage, degeneration, or impaired repair. The company's research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and regenerating muscle tissue.

Satellos' lead product candidate is SAT-3247, an orally administered small-molecule therapy designed to enhance the activation and function of muscle stem cells. The company is evaluating this approach for potential use in diseases characterized by progressive muscle weakness, including Duchenne muscular dystrophy and other muscle disorders.

Satellos Bioscience is headquartered in Vancouver, British Columbia, and is developing its therapies for international pharmaceutical and biotechnology markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.